HomeGLTO • NASDAQ
Galecto Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 2.60M | -54.73% |
Net income | -2.53M | 53.75% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -2.59M | 54.78% |
Effective tax rate | -0.08% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 11.94M | -56.06% |
Total assets | 15.37M | -52.69% |
Total liabilities | 1.66M | -61.65% |
Total equity | 13.71M | — |
Shares outstanding | 1.32M | — |
Price to book | 0.35 | — |
Return on assets | -39.99% | — |
Return on capital | -43.77% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -2.53M | 53.75% |
Cash from operations | -2.44M | 58.91% |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | -2.24M | -497.86% |
Free cash flow | -1.40M | 58.23% |
Previous close
$3.27
Day range
$3.00 - $3.30
Year range
$2.01 - $16.07
Market cap
4.35M USD
Avg Volume
69.40K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Founded
2011
Headquarters
Website
Employees
5
